Tim Tasker
YOU?
Author Swipe
View article: A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M <sub>1</sub> receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M <sub>1</sub> receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease Open
Introduction This study examined the safety and pharmacodynamic effects of selective muscarinic M 1 receptor orthosteric agonist HTL0018318 in 60 patients with mild‐to‐moderate Alzheimer's disease (AD) on background donepezil 10 mg/day. Me…
View article: Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M<sub>1</sub>‐acetylcholine receptor agonist: A randomized cross‐over trial
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M<sub>1</sub>‐acetylcholine receptor agonist: A randomized cross‐over trial Open
Aims HTL0009936 is a selective M 1 muscarinic receptor agonist in development for cognitive dysfunction in Alzheimer's disease. Safety, tolerability and pharmacokinetics and exploratory pharmacodynamic effects of HTL0009936 administered by…
View article: Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study Open
Background The cholinergic system and M 1 receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M 1 receptor partial agonist HTL0018318 is under development for the symptomatic treatment of D…
View article: First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub>‐receptor partial agonist for the treatment of dementias
First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub>‐receptor partial agonist for the treatment of dementias Open
Aims HTL0018318 is a selective M 1 receptor partial agonist currently under development for the symptomatic treatment of cognitive and behavioural symptoms in Alzheimer's disease and other dementias. We investigated safety, tolerability, p…
View article: P3‐025: USE OF A MODIFIED HIDDEN PATHWAY MAZE TEST IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
P3‐025: USE OF A MODIFIED HIDDEN PATHWAY MAZE TEST IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA Open
Maze tests have a long history as measures of visuospatial learning and executive function. The importance of impairments in both visuospatial learning and executive dysfunction has been increasingly recognized in early AD. In contrast to …